- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on HER2/Neu Over-expressing Locally Advanced Breast Cancer
Total 350 results
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
Amunix, a Sanofi CompanyMerck Sharp & Dohme LLCRecruitingLocally Advanced or Metastatic HER2-Expressing CancersAustralia, Spain, France, Portugal
-
Centre Oscar LambretTerminatedBreast Cancer | Metastasis | Sur-expressing Her2-neuFrance
-
Northwestern UniversityNational Cancer Institute (NCI)Not yet recruitingMetastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast CancervUnited States
-
National Cancer Institute (NCI)CompletedBreast Cancer | Breast Neoplasms | Adenocarcinomas | Metastatic Solid Tumors Characterized by HER2/Neu ExpressionUnited States
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyTerminatedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2/Neu-positive Breast CancerUnited States
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Instituto do Cancer do Estado de São PauloFundação Faculdade de MedicinaTerminatedLocally Advanced HER2-negative Breast CancerBrazil
-
Instituto do Cancer do Estado de São PauloFundação Faculdade de MedicinaTerminatedLocally Advanced HER2-positive Breast CancerBrazil
-
Hoffmann-La RocheCompletedHER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast CancerIndia
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma | Locally Advanced HER2-Negative...United States
-
Melinda TelliPfizer; BioMarin PharmaceuticalCompletedAdvanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast CancerUnited States
-
Hoffmann-La RocheWithdrawnBreast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
-
Tianjin Medical University Cancer Institute and...Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingHER2+ Early or Locally Advanced Breast Cancer
-
PfizerCompletedHR+/HER2- Locally Advanced, Metastatic Breast CancerUnited Kingdom
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States, South Africa
-
Japan Breast Cancer Research GroupChugai PharmaceuticalUnknownHER2-positive Locally Advanced or Metastatic Breast CancerJapan
-
AstraZenecaDaiichi SankyoNot yet recruitingMetastatic Breast Cancer | HER2-positive Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerCanada
-
Yongsheng WangJiangsu HengRui Medicine Co., Ltd.RecruitingLocally Advanced Breast Cancer | Hormone Receptor Positive,HER2-negative Breast CancerChina
-
Samsung Bioepis Co., Ltd.CompletedHER2 Positive Early or Locally Advanced Breast CancerCzechia
-
Cancer Trials IrelandTerminatedMetastatic Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast CancerIreland, Spain
-
EnhancedBio USA Inc.ZenopharmRecruitingMetastatic Breast Cancer | Locally Advanced Breast Cancer | HER2-Negative | Estrogen Receptor-PositiveUnited States, Korea, Republic of
-
University of WashingtonBreast Cancer Research FoundationNot yet recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma | Locally Advanced Unresectable HER2-Negative Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor-Positive...United States
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Biocon Biologics UK LtdNot yet recruitingHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
-
Celldex TherapeuticsCompletedMetastatic gpNMB Over-expressing Triple Negative Breast CancerUnited States, France, Spain, Italy, Canada, Germany, Australia, Belgium, United Kingdom
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
University Hospital, AkershusVestre Viken Hospital Trust; NovartisRecruitingBreast Cancer | Locally Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Luminal A Breast Cancer | Luminal B Breast CancerNorway
-
National Cancer Institute (NCI)TerminatedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive and other conditionsUnited States
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyRecruitingMetastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerAustria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
-
National Cancer Institute (NCI)CompletedRecurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7United States, Puerto Rico
-
Fudan UniversityRecruitingBreast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)China
-
Introgen TherapeuticsCompletedLocally Advanced Breast Cancer (LABC)United States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityJiangsu HengRui Medicine Co., Ltd.Active, not recruitingBreast Cancer | Neoadjuvant Therapy | Hormone Receptor-positive Breast Cancer | HER2-low-expressing Breast CancerChina
-
Royal Marsden NHS Foundation TrustPfizer; Breast Cancer NowRecruitingMetastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Recurrent Breast Cancer | ER+ Breast CancerUnited Kingdom
-
Alison StopeckRecruitingBreast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | TNBC, Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Neoadjuvant ChemotherapyUnited States
-
Daiichi SankyoRecruitingBreast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast CancerChina
-
National Cancer Institute (NCI)CompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | HER2/Neu PositiveUnited States, Puerto Rico
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingHER2/Neu Negative | Estrogen Receptor-positive Breast Cancer | Stage IV Breast Cancer AJCC v6 and v7United States
-
Fudan UniversityRecruiting
-
University of WashingtonNational Cancer Institute (NCI); National Center for Complementary and Integrative...CompletedStage IV Breast Cancer | Recurrent Breast Carcinoma | HER2/Neu PositiveUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHR Positive/HER2 Low Expression Metastatic Breast CancerChina
-
QuantumLeap Healthcare CollaborativeRecruitingBreast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2/Neu PositiveUnited States
-
Hospices Civils de LyonCompletedLocally Advanced Breast Cancer | Ductal Histologic Type | Without Her 2 OverexpressionFrance
-
AstraZenecaCompletedAdvanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene MutationUnited States, United Kingdom